Health Library Integrase Inhibitors for HIVFrom Healthwise

Raltegravir is available as pills. Usually, a pill is taken twice a day.

Raltegravir blocks the HIV integrase enzyme. This prevents HIV from multiplying. When the amount of virus in the blood is kept at a minimum, the immune system has a chance to recover and grow stronger.

Raltegravir is used in combination with other antiretroviral medicines to treat HIV. It helps prevent the virus from spreading in the body and reduce the amount of virus in your blood ( viral load). Raltegravir may be effective for people who have taken other anti-HIV drugs without success.

The use of three or more antiretroviral medicines (highly active antiretroviral therapy, or HAART) is the usual treatment for HIV infection.

The combination of medicines used for HAART will depend on your health, other conditions you might have (such as hepatitis), and results of testing. Talk to your doctor about the best treatment plan for you.

Treatment guidelines suggest the following for people with HIV:¹

• When considering treatment, experts currently consider your CD4+ cell count and the presence or absence of symptoms much more important than your viral load.
• If your CD4+ cell count is below 350 cells per microliter (mcL), you should begin treatment to stabilize and increase your CD4+ cell count.
• If your CD4+ cell count is more than 350 cells per microliter (mcL), treatment may be offered to help keep your immune system healthy and prevent AIDS.
• If treatment is not started, your condition will be monitored with frequent CD4+ cell counts.
• If you have symptoms of HIV or AIDS, you should consider starting treatment, whatever your CD4+ cell count is.
• If you are pregnant, you should be treated to prevent your unborn baby (fetus) from becoming infected with HIV.
• If you also have hepatitis B and are starting treatment for it, you should begin treatment for HIV as well.

Raltegravir works well with other antiretroviral medicines to improve CD4+ cell counts and reduce viral load.²

The most common side effects of raltegravir include diarrhea, nausea, headache, and fever.

See Drug Reference for a full list of side effects. (Drug Reference is not available in all systems.)

The U.S. Food and Drug Administration (FDA) approved raltegravir for people who have already been taking other anti-HIV medicines. It is not approved for use by people who are just starting drug treatment for HIV infection.

Raltegravir should be used to treat a pregnant woman only if the potential benefit is greater than the risk to the unborn baby (fetus).

Complete the new medication information form (PDF)(What is a PDF document?) to help you understand this medication.

Citations

1. U.S. Department of Health and Human Services (2007). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Adult and Adolescent Guidelines. Available online: http://www.aidsinfo.nih.gov/guidelines/GuidelineDetail.aspx?MenuItem=Guidelines&Search=Off&GuidelineID=7&ClassID=1.

2. Markowitz M, et al. (2007). Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: Results of a 48-week controlled study. Journal of Acquired Immune Deficiency Syndromes, 46(2): 125–133.

Author:	Maria G. Essig, MS, ELS	Last Updated: May 8, 2008
Medical Review:	Caroline S. Rhoads, MD - Internal Medicine Peter Shalit, MD, PhD - Internal Medicine
© 1995-2008 Healthwise, Incorporated. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated. This information does not replace the advice of a doctor. Healthwise disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. How this information was developed to help you make better health decisions.